IMMUNOTHERAPY
Clinical trials for IMMUNOTHERAPY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOTHERAPY trials appear
Sign up with your email to follow new studies for IMMUNOTHERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple therapy shows promise against rare sarcomas
Disease control OngoingThis study tests a combination of two immunotherapy drugs (pembrolizumab and eftilagimod alpha) plus radiation before surgery for adults with soft tissue sarcoma. The goal is to see if this approach shrinks tumors more effectively. About 40 participants with high-risk, non-spread…
Matched conditions: IMMUNOTHERAPY
Phase: PHASE2 • Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology • Aim: Disease control
Last updated May 26, 2026 04:01 UTC
-
New combo therapy shows promise for esophageal cancer patients
Disease control OngoingThis study tests whether giving the immunotherapy drug camrelizumab along with standard radiation before surgery can help shrink tumors in people with esophageal cancer. About 25 adults with operable cancer will receive the combination, then have surgery 4-8 weeks later. The goal…
Matched conditions: IMMUNOTHERAPY
Phase: PHASE1, PHASE2 • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
Nanoparticles + radiation + immunotherapy: a new triple attack against advanced cancers enters human testing
Disease control OngoingThis early-phase study tests a new treatment for people with advanced cancers that have not responded well to standard care. The treatment combines NBTXR3 (tiny particles injected into the tumor), radiotherapy, and an immunotherapy drug (anti-PD-1). The goal is to see if this tri…
Matched conditions: IMMUNOTHERAPY
Phase: PHASE1 • Sponsor: Nanobiotix • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
Triple therapy shows promise for tough liver cancers
Disease control OngoingThis study looked at 17 adults with intermediate to advanced liver cancer that could not be removed by surgery. They received a sequence of three treatments: a procedure to block the tumor's blood supply (TACE), precise radiation (SBRT), and drugs that help the immune system atta…
Matched conditions: IMMUNOTHERAPY
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New drug shows promise in shrinking lung tumors before surgery
Disease control OngoingThis study tests a new drug called Ivonescimab in people with non-small cell lung cancer who need surgery. The drug is given before surgery to shrink tumors and make them easier to remove. Researchers compare it to standard treatments and also study how it works in the body. Abou…
Matched conditions: IMMUNOTHERAPY
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New combo therapy shows promise for tough esophageal cancer
Disease control OngoingThis study tests whether giving immunotherapy plus chemotherapy before the usual chemoradiation can help people with advanced esophageal cancer that cannot be surgically removed. About 50 adults with this type of cancer will receive the combination treatment, then chemoradiation.…
Matched conditions: IMMUNOTHERAPY
Phase: PHASE2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Tissue collection study aims to build smarter cancer test
Knowledge-focused OngoingThis study collects fresh tumor samples from 416 adults with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) to develop and train a live tumor diagnostic platform. The goal is to see how accurately the platform can predict whether a pa…
Matched conditions: IMMUNOTHERAPY
Sponsor: Elephas • Aim: Knowledge-focused
Last updated May 26, 2026 04:01 UTC
-
Gut bacteria may hold key to lung cancer therapy outcomes
Knowledge-focused OngoingThis study looks at whether bacteria from throat swabs, stool, and lung samples can help predict which patients with stage III lung cancer will have their cancer return during immunotherapy (durvalumab) after chemoradiation. Researchers will also check if antibiotics affect treat…
Matched conditions: IMMUNOTHERAPY
Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC